A paradigm shift in mucosal vaccinology: NanoCF501 as a mechanistically grounded, clinically viable STING-targeting adjuvant
-
-
REFERENCES
[1] Liu Z., Zhou J., Gao R., et al. (2026). Precision-engineered STING agonist nanoparticles enable coordinated mucosal-systemic immunity for durable pan-β-coronavirus protection. Nat. Nanotech. 17:1-4. DOI:10.1038/s41565-026-02188-z [2] Wang X., Huang Z., Xing L., et al. (2025). STING agonist-based ER-targeting molecules boost antigen cross-presentation. Nature 641:202−210. DOI:10.1038/s41586-025-08758-w [3] Cromer D., Juno J. A., Khoury D., et al. (2021). Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 21:395−404. DOI:10.1038/s41577-021-00550-x [4] Camell C. D., Yousefzadeh M. J., Zhu Y., et al. (2021). Senolytics reduce coronavirus-related mortality in old mice. Science 373:eabe4832. DOI:10.1126/science.abe4832 [5] Ye T., Jiao Z., Li,X., et al. (2023). Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature 624:630−638. DOI:10.1038/s41586-023-06809-8 -
ABOUT THIS ARTICLE
Cite this article:
Xi E., Sun F., Chen L., et al. (2026). A paradigm shift in mucosal vaccinology: NanoCF501 as a mechanistically grounded, clinically viable STING-targeting adjuvant. The Innovation Materials 4:100233. https://doi.org/10.59717/j.xinn-mater.2026.100233
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Xi E., Sun F., Chen L., et al. (2026). A paradigm shift in mucosal vaccinology: NanoCF501 as a mechanistically grounded, clinically viable STING-targeting adjuvant. The Innovation Materials 4:100233. https://doi.org/10.59717/j.xinn-mater.2026.100233
Format
Content
DownLoad:
-
Figure 1.
Schematic illustrations of NanoCF501 acted as a STING-Targeting Adjuvant in Mucosal Vaccinology.
